In this section: Publications archive I Home Dialysis Survey I Indigenous kidney health statistics & reports
For Health Professionals: CKD in Australia I Detecting CKD I GFR Calculator (CKD-EPI formula)
Chronic Kidney Disease Management in General Practice
The 2nd edition of our popular CKD Management in General Practice supercedes the previous version and contains important new information.
- New CKD staging system and colour-coded action plans
- New recommendations albuminuria
- New eGFR recommendations
- New blood pressure targets
This book is available for PDF download - or in hard-copy.
You may also order this booklet by using this special Order Form. Send this form by email, with your contact details to KCAT@kidney.org.au - overseas order are not available.
Formally endorsed by RACGP, the ANZSN and Kidney Health Australia
Renal Drug Reference Guide
Following introductory principles on the use of drugs in patients with renal impairment, the Renal Drug Reference Guide is structured into 13 colour coded therapeutic chapters including; anaemia, analgesia, antihistamines, anti-infectives, cardiovascular, endocrine & metabolic disorders, gastrointestinal, genitourinary, immunosuppressants, musculoskeletal, neurology & psychotropics. As well as being evidence based, this information is practical and written expressly for the prescriber searching for easy to comprehend, definitive advice.
$77A each - Contact author: Matthew Cervelli +61 408 846 901 or email email@example.com
Edited by Matthew Cervelli, Forward by Dr Tim Mathew (KHA Medical Director) Professor Graeme Russ (Queen Elizabeth Hospital) and published with assistance of Kidney Health Australia and unrestricted support of various pharmaceutical industry partners. Guide intended for healthcare professionals who are able to exercise independent professional clinical judgement when using the information contained within. It is not intended use by healthcare consumers.
A decade after the KDOQI CKD Guidelines: a perspective from Australia
American Journal of Kidney Disease Volume 60 Issue 5, pages 725-726, November 2012, for full text article
Absolute Cardiovascular Risk Guidelines
Australian Guidelines for the management of absolute cardiovascular disease risk (May 2012)
Developed by National Vascular Disease Prevention Alliance (NVDPA) after approval by National Health and Medical Research Council (NHMRC). The guidelines incorporate and build on the earlier NVDPA Guidelines for the assessment of absolute cardiovascular disease risk (2009) and consolidate a number of other evidence-based guidelines related to primary prevention of cardiovascular disease (CVD). These guidelines are an important step as they provide a single preventive approach to first-ever CVD in Australia. Clinical decisions based on absolute risk can lead to improved health outcomes by identifying people most at risk and directing the right treatments to them. These links to relevant resources, support these guidelines.
STUDIES IN COLLABORATION WITH KIDNEY HEALTH AUSTRALIA
Projections of the incidence of treated End-Stage Kidney Disease in Australia, 2010-2020
AIHW catalogue number (PHE150)
Internet only - 14 September 2011 INTERNET ONLY ISBN 978-1-74249-201-8; Cat no PHE 150; 64pp
This report presents projections for end-stage kidney disease treated with dialysis or kidney transplantation (treated ESKD) for period 2010 to 2020. Projections are set out by sex at national and state/territory levels, and for ESKD patients with diabetes when commencing treatment.
The incidence of treated ESKD is projected to continue to rise, increasing by nearly 80% between 2009 and 2020 The proportion of those commencing ESKD treatment with diabetes is also expected to increase, from 45% in 2009 to 64% in 2020.
Economic Impact of End-Stage Kidney Disease in Australia - Projections to 2020
Read Executive Summary or full report November 2010
The cost of treating end-stage kidney disease from 2009 to 2020 is estimated to be around $12 billion to the Australian Government. This reports reveals the incidence of kidney disease is growing at a serious rate, projected to increase by more than 54% to 2020. Report estimates that increasing the use of home dialysis over the next 10 years would lead to an estimated net savings of between $378 and $430 million for our health system. Annual costs per person for home dialysis is $49,137, compared to $79,072 for hospital dialysis.
Contributors: Alan Cass, Steven Chadban, Martin Gallagher, Kirsten Howard, Alexandra Jones, Stephen McDonald, Paul Snelling and Sarah White. Corresponding author: Prof Alan Cass, Senior Director, George Institute for Global Health, PO Box M201 (Missenden Rd) Sydney 2050 Australia - call 02 9993 4553.
Kidney Health Australia commissioned these reports to establish comprehensive research into the economic burden of kidney disease in Australia. Research undertaken and reports written by The George Institute for International Health in collaboration with University of Sydney, Royal Prince Alfred Hospital, Queen Elizabeth Hospital and ANZDATA Registry.
Burden of Chronic Kidney Disease in Australia 2006 set out in two parts
Economic Impact of End-Stage Kidney Disease in Australia
Cost-effectiveness of Early Detection and Intervention to Prevent Progression of CKD in Australia
Two of a KinD (Kidneys in Diabetes) Access Report
This report concludes that an annual and simple kidney health test (a urine test followed by a blood test for those with excess protein in their urine) would prolong the lives of thousands of type 2 diabetes patients and significantly reduce the need for kidney dialysis and transplantation.
Two of a KinD (Kidneys in Diabetes) Access Report - Key Findings.
Report commissioned by Kidney Health Australia to quantify the burden of diabetic kidney disease in Australia and the cost effectiveness of screening people with type 2 diabetes - released 17 June 2011
Contributors: Dr Tim Mathew, Medical Director - Kidney Health Australia, Dr Mukesh Haikerwal AO, Professor Stephen Colagiuri - University of Sydney. We thank Dr Jonathan Shaw from Baker IDI Heart and Diabetes Institute, for providing access to unpublished data from AusDiab, and Professor Alan Cass - The George Institute for Global Health, for providing data on previous modelling undertaken on cost effectiveness of screening for CKD. We also thank Brian Livingston and Associate Professor Stephen McDonald - ANZDATA, for their efficiency in assisting with additional data. Research undertaken and report prepared by Deloitte Access Economics for Kidney Health Australia, funded by an unconditional grant from Boehringer Ingelheim. In no way has Boehringer Ingelheim had any part in the direction, analysis or findings contained within this report.
AUSTRALIAN INSTITUTE OF HEALTH AND WELFARE REPORTS (AIHW) - RELATING TO KIDNEY DISEASE
Direct link to all AIHW reports on Chronic Kidney Disease (CKD)
New website - Indigenous Observatory AIHW in collaboration with Aust. Bureau of Statistics (ABS)
KHA webpage - Indigenous Statistics
Latest AIHW report of interest:
Multiple causes of death in Australia: an analysis of all natural and selected chronic disease causes of death 1997-2007 AIHW Canberra 2012. AIHW bulletin no 105. Cat no AUS 159.
This bulletin is the first comprehensive application of multiple causes of death statistics to natural causes of death and specific chronic diseases of public health importance in Australia. Useful for guiding and improving policy for reducing deaths from these chronic diseases and for targeting investment in health prevention. When describing patterns of causes of death using only the underlying cause, important cause information is overlooked. Analyses using multiple cause data complement routine descriptions of mortality that use only the underlying cause and offer broader insight into the disease processes occurring at the end of life.
Join our Kidney Community today - to receive our monthly Kidney News which brings you clinical and non clinical information from the kidney world and updates on our professional programs. Subscribe via email to firstname.lastname@example.org providing your name, professional details, city, state, country and interest in CKD.
Do you have patients considering Home Dialysis?
A complete education resource on this topic including a developing area specifically for health professionals can be found at our sister website www.homedialysis.org.au
Electricity and Home Dialysis
ANZ/AS3003 is the standard that governs electricity regulations pertaining to home dialysis, both home haemodialysis and peritoneal dialysis. All home dialysis units should be aware of their responsibilities related to this and other standards. Refer to this summary - Electricity and Home Dialysis.
Disclaimer: The intent of this document is to provide information to renal units. All information presented is an interpretation of the relevant Australian Standards Legislation, as at February 2012. KHA and the HDAC hold no responsibility for changes to the legislation. The legislation does not necessarily reflect the views of KHA or the HDAC. Electrical installers must obtain original copies of all legislation.
Financial concessions and Travel Reimbursement for Home Dialysis
Patients on Home Dialysis treatment may be eligible for financial assistance for costs related to, but not exclusive to electricity and water. The HOME Network has put together Fact Sheets (see links below) provide a guide to concessions available in each State of Australia.
Essential Medical Equipment Payment
Centrelink pays an annual $140 payment to people who experience additional increases in home energy costs from the use of Essential Medical Equipment to manage their disability or medical condition. This applies to a Home Dialysis Unit. See www.cleanenergyfuture.gov.au/household-assistanceessential
Comprehensive summary provides general information and links to relevant agencies
Financial Support for Home Dialysis Patients in Australia update February 2012
KHA webpages: Kidney Check Australia Taskforce (KCAT) I KHA - CARI Guidelines
Patient Education Resources: Fact Sheets I Health Publications I Transplantation I Resource Order Form
This site complies with HONcode standards for trustworthy health information: verify here
Kidney Health Australia is an approved health information partner of
UPDATED 12 MAY 2013
Disclaimer: This is intended as a general introduction to this topic and is not meant to substitute for your doctor's or health professional's advice. All care is taken to ensure the information is relevant and applicable to each Australian state. It should be noted Kidney Health Australia recognises each person's experience is individual and variations do occur in treatment and management due to personal circumstances. Should you require further info always consult your doctor or health professional.